8-K/A: Eyenovia Updates Investor Presentation, Clarifies Market Opportunities and Apersure NDA Costs

Eyenovia has amended its previous 8-K filing to update its investor presentation, clarifying market size opportunities and the cost of an NDA filing for Apersure.

Summary

• Eyenovia has updated its investor presentation, focusing on market opportunities and the cost of an NDA filing for Apersure.
• The updated presentation clarifies market size opportunities for its products and the cost of an NDA filing for Apersure.
• The company's Optejet technology is designed to deliver ophthalmic medications with greater precision and less drug volume than traditional eye drops.
• Eyenovia's product pipeline includes Mydcombi for pupil dilation, APP13007 for post-surgical pain and inflammation, and MicroPine for pediatric myopia.
• Mydcombi is already commercially available, targeting a $250 million annual market.
• APP13007 has a PDUFA date of March 4, 2024, and is expected to launch in the second half of 2024, targeting a $700 million market.
• MicroPine is in Phase 3 development for pediatric myopia, with a potential $1.8 billion annual market opportunity in the U.S. alone.
• The company is also exploring opportunities in glaucoma ($2.7 billion), acute dry eye ($236 million), and chronic dry eye ($2.1 billion).
• Eyenovia's Optecare digital platform aims to improve patient compliance and provide additional revenue streams for doctors.
• The company has a strong intellectual property portfolio with many claims in effect beyond 2031.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Eyenovia, highlighting the potential of its technology and product pipeline. The clinical results for APP13007 are particularly encouraging, and the company has a clear plan for future development and commercialization. The company has a strong IP portfolio and experienced management team. The only negative is the delay in the Apersure NDA.

Positives

• The Optejet technology offers a more precise and efficient way to deliver ophthalmic medications.
• Eyenovia has a diverse product pipeline targeting large markets with significant unmet medical needs.
• The company has a strong intellectual property portfolio protecting its technology.
• The Optecare digital platform provides a potential additional revenue stream and improves patient outcomes.
• Mydcombi is already commercially available and has received positive testimonials from early adopters.
• APP13007 has shown strong clinical results and has a convenient twice-daily dosing schedule.
• Eyenovia has re-acquired the development rights to MicroPine, which has a large market opportunity.
• The company has a clear plan for the development and commercialization of its products.
• The company has an experienced leadership team.

Negatives

• The NDA filing for Apersure is on hold pending improvement in the presbyopia market.
• The development of MicroPine is subject to regulatory approvals and clinical trial outcomes.
• The company is reliant on third parties for the development and commercialization of some of its products.
• The company faces competition from other companies in the ophthalmic market.

Risks

• Clinical trial results may not be positive or statistically significant.
• Regulatory approvals may be delayed or not granted.
• Market acceptance of the company's products may be slower than expected.
• The company may face challenges in scaling up manufacturing and commercialization.
• The company may face intellectual property challenges.
• Changes in the legal, regulatory, legislative and geopolitical environments could impact the company's ability to obtain regulatory approval for its products.
• The company may face competitive pressures from other companies in the ophthalmic market.

Future Outlook

Eyenovia plans to launch APP13007 in 2H 2024, pending approval, and is working towards an NDA submission for MicroPine in 2H 2026 or 2H 2027, depending on clinical trial results. The company also sees potential applications for the Optejet in glaucoma, acute dry eye, chronic dry eye, and eye hydration.

Management Comments

• 'My staff and the patients love the technology. MydCombi provides good dilation without the burning associated with in-office dilation.' Edward Rubinchik, MD
• 'MydCombi is a no brainer. Patients tolerated the medication better due to the Optejet device, and it saves our technicians work up time vs. using three eye drops.' Ed Yung, MD
• 'MydCombi is easier to use for patients with difficult eye anatomies than eye drops. Theres no chance of contamination as MydCombi doesnt touch the patients' eyes.' Krystina Feliciano, Ophthalmic Tech
• 'Patients are dilating faster and get back to normal faster. Its easy to use by my technicians.' Aleksandra Wianecka, OD
• 'MydCombi has been a fantastic addition to our office in the age of streamlined medicine and has been welcomed by our patients.' Nathan Radcliffe, MD
• 'MydCombi is easy to handle, and the effectiveness is similar to eye drops with patients experiencing more comfort when instilled.' Dan Tran, MD

Industry Context

Eyenovia is operating in the ophthalmic market, which is characterized by a need for more effective and convenient drug delivery methods. The company's Optejet technology and digital platform address these needs, positioning it to compete with traditional eye drops and other emerging technologies. The company is also targeting large markets with significant unmet medical needs, such as myopia and post-surgical pain and inflammation.

Comparison to Industry Standards

• Traditional eye drops have been criticized for their poor usability and dosing precision, which Eyenovia's Optejet aims to address.
• Competitors in the mydriasis market include traditional eye drops containing tropicamide and phenylephrine, which Mydcombi aims to replace with a more convenient and effective spray.
• In the post-surgical pain and inflammation market, APP13007's twice-daily dosing is a significant advantage over the four-times-daily dosing of many existing treatments, such as dexamethasone, difluprednate, and prednisolone.
• For pediatric myopia, Eyenovia's MicroPine competes with atropine eye drops and contact lenses, offering a potentially more convenient and compliant treatment option.
• Companies like Sydnexis, Vyluma, and Ocumension are also developing atropine drops for myopia, but Eyenovia's spray delivery and digital platform offer a unique approach.

Stakeholder Impact

• Shareholders may benefit from the potential growth and revenue opportunities presented by Eyenovia's product pipeline.
• Employees may benefit from the company's growth and success.
• Patients may benefit from the more effective and convenient drug delivery methods offered by Eyenovia's technology.
• Doctors may benefit from the Optecare platform, which provides additional revenue streams and improves patient outcomes.
• Suppliers and creditors may benefit from the company's growth and financial stability.

Next Steps

• Eyenovia plans to launch APP13007 in 2H 2024, pending FDA approval.
• The company plans to meet with the FDA to discuss possible changes to the Phase 3 MicroPine clinical trial protocol.
• Eyenovia plans to submit an NDA for MicroPine in 2H 2026 or 2H 2027, depending on clinical trial results.
• The company will continue to explore opportunities in glaucoma, acute dry eye, chronic dry eye, and eye hydration.

Key Dates

Keywords

Optejet, ophthalmic, mydriasis, myopia, APP13007, MicroPine, Mydcombi, presbyopia, glaucoma, dry eye, drug delivery, digital health, FDA, clinical trials, NDA